Cleerly

Cleerly, with the slogan "Personalized precision heart health," is a Health Care startup founded in 2017, headquartered in the United States. The company is dedicated to eliminating heart attacks by establishing a new standard of care for diagnosing heart disease. Cleerly leverages AI-empowered solutions to support comprehensive phenotyping of coronary artery disease through the evaluation of advanced non-invasive CT imaging. Their approach is built on almost 20 years of science from landmark multi-center clinical trials, aiming to enhance health literacy for all stakeholders in the coronary care pathway. The most recent milestone for Cleerly was a $223.00M Series C investment on 25 July 2022. This investment was led by a syndicate of prominent investors including Novartis, T. Rowe Price, Catalytic Impact Foundation, Cigna Ventures, DigiTx Partners, LRV Health, Mirae Asset Capital, Presight Capital, Vensana Capital, and Peter Thiel. This substantial investment is a testament to the confidence that industry leaders have in Cleerly's mission and the potential of its AI-driven approach to revolutionize heart health care. With the support of these investors, Cleerly is well-positioned to continue its groundbreaking work towards preventing heart attacks and improving cardiovascular health outcomes.